Lonza's softgel interests wane with sale of European sites
Lonza is to sell off two European sites to NextPharma in a deal that gives the contract development and manufacturing firm facilities to work with lipid oral dosage forms for the nutrition and pharma markets. The production sites in Ploermel in France and Edinburgh in the UK, employs around 260 and 130 permanent staff respectively and produces liquid-filled hard capsules (including Licaps) and softgels (including for high potent and hormonal products). “NextPharma ...
Source: nutraingredients.com